Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as believe , could , should envisage , estimate , intend , may , plan , potentially , expect , will or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors current expectations and assumptions regarding the Company s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors current beliefs and assumptions and are based on information currently available to the Directors.
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its unaudited interim results for the six months ended 30 September 2020. · Dr Huw Jones appointed as Chief Executive Officer · Completion of first out-licensing deal with Juvenescence for use of Sulforadex® technology in non-pharmaceutical markets. Up to $10.5m receivable in milestones with royalties on sales · Phase IIb/III trial using SFX-01 for acute respiratory distress syndrome ( ARDS ) including COVID-19 patients sponsored by Dundee University, with grant funding from LifeArc; the STAR trial ( SFX-01 treatment for acute respiratory infections) · Patient recruitment commenced in STAR trial post the period end with data potentially available in Q4 2021.